Crucell: Investors

Home | Contact | Search | Site Map

About Us

	Corporate Profile
	Share Information
	Financial Information
	Press Releases
	Event Calendar
	Presentations
	Shareholder Services


	Sign up for messages to be conveniently delivered to your email whenever new company information is posted.


	Sign up here to receive Crucell’s newsletter.

It is Crucell’s goal to improve healthcare throughout the world by fighting infectious diseases. Crucell does this by discovering, researching and developing technologies, vaccines and antibodies, using its own fully integrated infrastructure for in-house development, production and marketing and, where useful or necessary, by forging partnerships with other companies and organizations.

Robust product portfolio
As the leading independent vaccine company, Crucell presents a strong portfolio of products:

Hepavax-Gene® - a recombinant hepatitis B vaccine

Epaxal® - the only aluminium-free hepatitis A vaccine

Vivotif® - the only oral anti-typhoid vaccine

Inflexal® V - the virosomal vaccine against influenza

Quinvaxem™ - the first fully liquid pentavalent vaccine against diphtheria, tetanus, pertussis (whooping cough), hepatitis B and Haemophilus influenzae type b, one of the leading causes of bacterial meningitis in children.

Bringing innovation to global health
Headquartered in Leiden, The Netherlands, Crucell currently employs about 900 people and has subsidiaries in Switzerland, Spain, Italy and Korea. Crucell N.V. is listed on Euronext and NASDAQ (CRXL) and the SWX Swiss Exchange (CRX). At Crucell, we’re bringing innovation to global health.

For more information, please visit the About Us section.